Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191355 | 0.94 | TOP1 (0.75) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL2028767 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL22843988 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL25130176 | 0.92 | TOP1 (0.85) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL2028388 | 0.92 | TOP1 (0.85) | TOP1ALDH1A1GLAKDM4ETP53 | |
| Gimatecan SCHEMBL130586 | 0.91 | TOP1 (0.79) | TOP1ALDH1A1GLAKDM4ETP53 | |
| Gimatecan SCHEMBL15341182 | 0.91 | TOP1 (0.79) | TOP1ALDH1A1GLAKDM4ETP53 | |
| Gimatecan SCHEMBL1649254 | 0.91 | TOP1 (0.79) | TOP1ALDH1A1GLAKDM4ETP53 | |
| Gimatecan SCHEMBL24685122 | 0.91 | TOP1 (0.79) | TOP1ALDH1A1GLAKDM4ETP53 | |
| Gimatecan SCHEMBL29358288 | 0.91 | TOP1 (0.79) | TOP1ALDH1A1GLAKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-01-29 | — | — | US | claimed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | claimed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | claimed |
| EP-1814520-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CAMTOTHECIN DERIVATE | SIGMA TAU IND FARMACEUTI (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-8975248-B2 | Combinations of therapeutic agents for treating cancer | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-03-10 | — | — | US | disclosed |
| US-8518961-B2 | spontaneously dispersible; 7-t-butoxyiminomethylcamptothecin in microemulsion preconcentrate; topoisomerase I inhibitor; proliferative diseases including cancer; stability; bioavailability | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-08-27 | — | — | US | disclosed |
| US-20100166843-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CAMPOTHECIN DERIVATIVE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-07-01 | — | — | US | disclosed |
| US-20100068265-A1 | GELATIN CAPSULES COMPRISING AN ACID | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100028338-A1 | Gimatecan (7-t-butoxyiminomethylcamptothecin) and chemotherapeutic agents | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2120889-A1 | GELATIN CAPSULES COMPRISING AN ACID | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-2107903-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CAMPOTHECIN DERIVATIVE | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-10-14 | — | — | EP | disclosed |
| EP-1814520-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CAMTOTHECIN DERIVATE | Novartis AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-7105492-B2 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-09-12 | — | — | US | disclosed |
| WO-2006065780-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006053755-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CAMTOTHECIN DERIVATE | NOVARTIS AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-01-29 | — | — | US | disclosed |
| US-6589939-B2 | Also useful in treating viral infections; antiprotozoa (plasmodium) activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | disclosed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | disclosed |
| WO-2000053607-A1 | CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068265-A1 | GELATIN CAPSULES COMPRISING AN ACID | GLA, GYPA, PGA5 | TOP1 4286/4885ALDH1A1 397/4885GLA 1/4885 |
| US-20100028338-A1 | Gimatecan (7-t-butoxyiminomethylcamptothecin) and chemotherapeutic agents | HDAC6, HDAC1, HDAC8 | TOP1 21/4885ALDH1A1 3549/4885GLA 1037/4885 |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TYMP | TOP1 1/4885ALDH1A1 2202/4885GLA 1623/4885 |
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TOP2B | TOP1 1/4885ALDH1A1 1248/4885GLA 1972/4885 |
| US-20100166843-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CAMPOTHECIN DERIVATIVE | TOP1, TOP2A, TOP2B | TOP1 1/4885ALDH1A1 3296/4885GLA 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.